UnknownPhase 2

The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Australia158 participantsStarted 2022-04-13

Plain-language summary

The purpose of the ASCEND clinical trial is to measure the effect of adding LSTA1 (certepetide), compared to placebo, to chemotherapy (gemcitabine and nab-paclitaxel) in patients who have untreated metastatic pancreatic cancer. The study will assess the duration which the cancer remained stable or improved, the number of patients who responded to treatment, overall survival, side effects and quality of life.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Malignancy that was treated with curative intent and for which there has been no known active disease for ≥2 years prior to randomisation.
✕. Curatively treated non-melanoma skin cancer, cervical cancer in situ, superficial transitional cell carcinoma of the bladder, stage 1 endometrial carcinoma, prostatic intraepithelial neoplasia, low-grade papillary thyroid cancer, untreated localised very low risk or low risk prostate cancer under observation.

What they're measuring

Progression Free Survival

Timeframe: From date of randomization to 18 months later, or death

Trial details

NCT IDNCT05042128

SponsorAustralasian Gastro-Intestinal Trials Group

Sponsor typeNETWORK

Study typeINTERVENTIONAL

Primary completion2025-06-01

View on ClinicalTrials.gov More Pancreatic Ductal Adenocarcinoma trials